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Abstract
In the Cancer Genome Atlas (TCGA) project, gene expression of the same set of samples is measured multiple times on
different microarray platforms. There are two main advantages to combining these measurements. First, we have the
opportunity to obtain a more precise and accurate estimate of expression levels than using the individual platforms alone.
Second, the combined measure simplifies downstream analysis by eliminating the need to work with three sets of
expression measures and to consolidate results from the three platforms. We propose to use factor analysis (FA) to obtain a
unified gene expression measure (UE) from multiple platforms. The UE is a weighted average of the three platforms, and is
shown to perform well in terms of accuracy and precision. In addition, the FA model produces parameter estimates that
allow the assessment of the model fit. The R code is provided in File S2. Gene-level FA measurements for the TCGA data sets
are available from http://tcga-data.nci.nih.gov/docs/publications/unified_expression/.
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Introduction
The Cancer Genome Atlas (TCGA) project [1,2] aims to
understand the molecular basis of cancer by characterizing
different aspects of the cancer genome, including copy number,
methylation, mutation and gene expression. In the first phase of
the project, three microarray platforms are used to measure gene
expression levels in glioblastoma multiforme (GBM), ovarian and
lung squamous tumor samples: Affymetrix Human Genome HTS
U133A Array (U133), Affymetrix GeneChip Human Exon 1.0 ST
Array (Exon), and Agilent custom 244K Array (Agilent), giving us
three sets of gene expression measures on all the samples.
This article addresses the problem of combining gene expression
measures for the same set of samples from multiple platforms. A
combined measure is desirable because 1) we get a more reliable
estimate by using more information, and 2) downstream analysis
can be carried out on a single set of expression measures rather
than multiple. As shown in [3], different microarray platforms
have different performances, therefore simply taking an average of
the measurements from different platforms would not necessarily
be the optimal solution.
Our method was used to generate the unified expression
measures for TCGA glioblastoma multiforme (GBM) data, which
was used in Verhaak et al [4]. Other than the limited description
of our method there, we are not aware of any other work that
addresses this particular problem. However, much work has been
done to address the problem of combining expression data from
different platforms, where different samples are measured by
different platforms. For example, Warnat et al [5] proposed to use
median rank scores and quantile discretization to integrate
expression data from different studies for the purpose of supervised
classification analysis. Scharpf et al [6] proposed a hierachical
Bayesian model to integrate data from different studies and to
identify differentially expressed genes between two conditions.
Here, we propose to use factor analysis to address this problem.
The main advantage of using factor analysis to combine
concomitant expression measures is that it gives each platform a
weight depending on how well its measurements correlate with the
rest of the platforms and therefore has the ability to down-weight a
problematic platform. The underlying gene expression level is
reflected in the measurements obtained from each of the platforms
and is thought of as the latent variable in the factor analysis model.
Factor analysis has previously been used in the single-platform
setting as a summarization method for Affymetrix U133 platforms
[7], and was shown to perform comparably with Robust Multichip
Average (RMA) [8], which is a widely used summarization method
in the single-platform setting.
Factor analysis can be applied in two ways. One is to first
summarize the expression measures within each platform and
apply factor analysis to the platform summaries. We call this gene-
level FA. This method requires the gene of interest to be measured
on at least three platforms simultaneously. The second method,
probe-level FA, applies factor analysis directly to probe-level
measurements across all platforms. This eliminates the require-
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can provide estimates for all genes that are measured on any of the
platforms. Factor analysis as we do it requires more samples than
platforms, and is best when the number of samples greatly exceeds
the number of platforms. Our approach will not apply in a setting
such as the MAQC project [9], where the number of samples and
the number of platforms are very similar.
We have applied both gene-level and probe-level FA to
integrate the expression measures from U133, Exon and Agilent
arrays for TCGA GBM and ovarian tumor samples. We use
expression levels measured from digital sequencing (DGE)
experiments on a subset of these samples as our gold standard to
evaluate the performance of our FA models, as digital sequencing
has been shown to be highly reproducible and accurate in
identifying differentially expressed genes [10,11]. A simulation
study has been carried out to further understand the performance
of gene-level FA.
We compare the performances of gene-level and probe-level
FAs to each of the three platforms alone, as well as gene-level and
probe-level averages in terms of precision and accuracy. We find
that gene-level FA and gene-level average are the top performers
when evaluated by several criteria across all genes, followed by
probe-level FA. Our simulation study further shows that gene-level
FA has a clear advantage over gene-level average when two
platforms are giving good expression measurements and the third
is mis-behaving. This result is confirmed when we look at the
subset of such genes in the TCGA ovarian data set.
Methods
Data
We have applied the proposed FA models to 246 GBM samples
and 175 ovarian samples available through TCGA. This paper
focuses on the ovarian data set where digital sequencing data is
available for 31 of the 175 samples, which we use as a gold
standard to evaluate our methods. Each sample is measured on
three microarray platforms: U133, Exon and Agilent. Probes from
the three platforms are mapped to a transcript database compiled
from RefSeq and GenBank as described in [2,4]. For the
Affymetrix platforms, a minimum of five perfect matching probes
is required to define a new, gene-centric probe set. A minimum of
three perfect matching probes is required for the sparser Agilent
array. The new gene-centric probe set definitions ensure
independence from the manufacturer annotation and allow direct
comparisons between the different platforms. Using the new
definitions, 11,864 genes are represented on all three platforms
and are included in our analysis. Gene summaries are obtained
through the TCGA data portal (cancergenome.nih.gov) and are
used for gene-level FA. Background-corrected and normalized
probe-level data, generated from the raw data files available
through the TCGA portal, are used for probe-level FA. Please
refer to the TCGA Data Primer [12] for a detailed description of
sample acquisition, processing and data generation.
Proposed model
A thorough presentation of the factor analysis model can be
found in [13]. Here we provide a brief description of the model
when applied to generate the unified expression measure. Let ygij
be the observed expression measure on the log scale for gene g
from sample i and platform j, standardized to have mean 0 and
variance 1 across all the samples within each platform. For the
probe-level model, j indexes probes both within and across all
platforms. Let xgi denote the unobserved underlying expression
level we would like to estimate for gene g and sample i. Since the
factor analysis model is always applied gene by gene, we simplify
notation by omitting the subscript g from now on. The factor
model can be written as the following:
yij~bjxiz ij, ð1Þ
where xi is called the common factor, and the error term ij is
called the specific or unique factor in factor analysis literature. If
we consider xi, yij and ij to be realizations of the random variable
X, k-dimensional random vector Y, and k-dimensional random
vector W respectively, where k is the number platforms in gene-
level FA, or the number of probes in probe-level FA, the model
can be written as
Y~bXzW,
where b is a vector of length k, and the model is parameterized in
the following way:
X*N(0,1), W*N(0,Y), and Y*N(0,S),
where W is independent of X, Y is k|k and diagonal, and S is
k|k and has all 1’s on the diagonal. Here N(0,V) means
multivariate normally distributed with mean 0 and variance-
covariance matrix V, with the appropriate specialization if the
dimension is 1. The following are readily derived:
Var(Y)~Var(bXzW)~bb
TzY,
Cov(Y,X)~E½(bXzW)(X) ~b,
and
E(Xjy)~b
T(bb
TzY)
{1y: ð2Þ
It turns out that the right hand side of (2) is equal to
X ~(Izb
TY{1b)
{1YsTy,
which is call the Thomson’s factor score, also known as the
regression factor score [14]. The Thomson’s factor score
inverts a matrix of smaller dimension than the conditional
expectation in (2), and is used here to estimate the common
factor score X.
In order to obtain unified expression measures for a given gene
using Thomson’s factor score, we need to estimate the parameters
b and Y. The log likelihood of Y is
l(b,YjY)~{
N
2
logjbb
TzYj{
1
2
X
i
yT
i (bb
TzY)
{1yi
()
,
and the maximum likelihood estimates of the parameters b and Y
are obtained using an EM algorithm. Note that the likelihood is
invariant to orthogonal transformations of b, which is simply sign
flipping in this case, since ({b)({b)
T~bb
T.
Thomson’s factor score says that the unified expression measure
is a weighted average of the observed expression measures from
the k platforms, the vector b
T(bb
TzY)
{1 being the weights
Unified Gene Expression Measures
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observed expression measure on different platforms and the
unified expression measure we estimate, and that the weight given
to a platform increases with the b for that platform. The weights
do not necessarily sum up to 1, and can be negative in some cases.
We obtain the same unified expression measure even if the y’s
are mean-centered but not standardized as the factor analysis
model is scale invariant [14].
The factor analysis model is implemented using the R package
factanal.
Results
We find that factor analysis gives unified expression measures
that are highly correlated with well-performing platforms when a
gene is expressed and has a reasonable dynamic range across
samples. When a gene is expressed at background levels or has
constant expression levels across samples, we cannot get a good
estimate of the covariance matrix for that gene, and the factor
analysis model will not produce helpful results. However, these are
genes that are not of interest in most cases. By combining multiple
platforms, discordant measures from one platform can be rescued
by concordant measurements from the other two platforms. In
these situations, the factor model gives a more reliable estimate
than simply averaging measurements from all the platforms.
This section is organized as follows. We first describe the model
fit for gene-level FA and probe-level FA by showing a few genes
that are representative of the different situations, followed by a
comparison of gene-level FA and probe-level FA. We then
systematically evaluate the performance of our FA models in terms
of precision (variance) and accuracy (bias) by first comparing them
to five other gene expression summaries across all genes: gene-level
averages of the three platforms, probe-level averages across all
probes from the three platforms, and the three expression
measures from the three platforms. The accuracy of gene-level
FA and gene-level averages is then further compared using a
simulation study, the results of which are then confirmed in the
TCGA ovarian data set.
Model fit
Gene-level model. We illustrate the model fit in different
situations using four genes, shown in Figure 1.
When pair-wise correlations between platforms are high
(correlationw0.9, gene FHL1, Figure 1A), gene-level FA results
in unified expression measures that are highly correlated with each
of the platforms. Of the 11,864 genes present on all three
platforms, 55% have all three pair-wise correlations w 0.6, and
61% have all three ^ b b’s w 0.7. Recall that ^ b b’s are the correlations
between each platform and the unified gene expression (Figures S1
and S2, Table S1).
When the three platforms do not correlate, e.g. due to low
expression values or small dynamic ranges (e.g. gene TACR3,
Figure 1B), the model is not very helpful. Although the unified
expression measure correlates moderately with U133, it has a
negative correlation of modest size with Agilent, which is an
indication of poor model fit, and the results should be disregarded.
A few hundred genes have small or even negative ^ b b’s (Tables S2
and S3), which are usually associated with platforms with low
expression values or small dynamic ranges (Figure 2).
For 409 genes, two platforms correlate well with each other, but
not the third platform (one correlation w0:6 and two others
v0:4). In all of these cases, the two concordant platforms are
assigned high ^ b b values and the platform not correlating with the
rest gets a low ^ b b value (Figure S3). This may be related to mis-
annotation or novel gene structures. An example is the gene
SLC36A1 (Figure 1C), where the model gives unified expression
measures mostly based on U133 and Exon, which have good
correlation. A similar pattern is seen in the GBM data set for this
gene (Figure S4). DGE data also correlates better with U133 and
Exon than with Agilent (Figure S5). Upon further inspection, we
find the Agilent and U133 probes to target the 39 UTR region of
one of four possible transcripts of SLC36A1 with U133 probes on
the 39 side of Agilent probes, while Exon probes target all four
possible transcripts, according to Ensembl build hg19. It is possible
that the U133 probes target a novel transcribed region that is part
of the other three transcripts. There are 53 genes with one bad ^ b b
value (v0:5) when the gene is expressed at levels generally
considered to be above background (w6 for U133 and Exon,
w{2 for Agilent) with a dynamic range of w0:5 (as measured by
the inter-quartile range, IQR) on all three platforms, which are
likely due to annotation errors. For all of these cases, the low ^ b b
value is associated with the platform that is not concordant with
the other two (Figure S6).
In the last example (gene ZNF783, Figure 1D), the exon array is
at a reasonable expression level but with a relatively small dynamic
range of 0.6 and does not correlate with measurements from U133
or Agilent. In this case, unified expression measure is largely the
U133 measure. A situation such as this, where one of the ^ b b is near
1 is called a ‘‘Heywood case’’ in the factor analysis literature. This
is due to the constraint of Y§0. Heywood cases arise when the
optimization procedure yields a solution with negative ^ Y Y entries.
There are 2,159 genes in the ovarian data set where Heywood
cases occur. A large percentage of them are genes at low
expression levels and with small variation across samples, but quite
a few also occur when a gene is highly expressed or variable
(Figure S7). In all but 9 such genes, the platform with the negative
^ Y Y entry (and therefore a ^ b b near 1) is one of the two platforms with
the best pair-wise correlations. Therefore although undesirable,
the estimates obtained in these cases are still likely to be
reasonable, i.e. with best performing platforms assigned highest
weights, but should be used with caution. There are 1,341
Heywood cases in the GBM data set, where there are 246 samples,
consistent with the observation that they are less likely to occur
with the increase of sample size [13].
We use the bootstrap [15] to estimate the standard errors of our
^ b b. For most genes, the SE of ^ b b is less than 0:1 (Figure S8), meaning
that the unified gene expression estimates have reasonable
variances in most cases. Genes with large ^ b b SE’s (w0:2) are
usually expressed at low levels or have small dynamic ranges
(Figure S9). Of the genes with large ^ b b SE’s and IQR’s greater than
1 for exon and Agilent, only three have U133 median expression
levels greater than 4: RPS4Y1, COX6A2 and RPL23AP13, which all
have reasons to have unstable ^ b b estimates: RPS4Y1 has one very
obvious outlier sample in U133; COX6A2 has two obvious outlier
samples in Agilent; RPL23AP13 does not have any obvious outlier
samples but its gene summaries on the three platforms do not have
much correlation.
Probe-level model. Probe-level FA is applied to the 175
ovarian samples run on the same three platforms: U133, Exon,
and Agilent for the 11,864 genes represented on all three
platforms. Instead of applying the FA model on gene summaries
from each of the platforms, we now apply the model directly to
background-corrected and normalized probe measurements from
all three platforms, i.e. k is now the sum of the number of probes
on the three platforms, whereas in the gene-level model, k is 3, the
number of platforms.
The three platforms have different numbers of probes
interrogating a given gene. The exon array has the greatest
Unified Gene Expression Measures
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17691Figure 1. Four genes to illustrate gene-level FA: FHL1 (A), TACR3 (B), SLC36A1 (C) and ZNF783 (D). The top panels are pairs plots of the
gene-level summaries of the three platforms. The bottom panels are scatter plots of gene-level summaries from each platform versus the unified
expression values.
doi:10.1371/journal.pone.0017691.g001
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probes per gene for the majority of the genes. Agilent has about 2
to 8 unique probes per gene, and each probe is usually replicated
two to three times. So for a given gene, there are usually a total of
60 to 200 probes from the three platforms (Figure S10).
Two genes used as examples in the gene-level FA discussion are
shown here to illustrate the performance of probe-level FA.
In the case of highly expressed gene FHL1 (Figure 3A), most
probes track each other very well with a lot of variation across
samples. Some probes on the U133 and exon arrays do not work
as well (Figure S11). The exon array has the lowest within-
platform probe correlations, possibly due to alternative splicing,
and results in lower ^ b b estimates (Figure S12). Outlying probes on
U133 are also assigned lower ^ b b estimates. With problematic
probes down-weighted, it is not surprising to see in Figure 3C that
all reasonable methods give highly correlated estimates.
Of course, not all genes perform as well as FHL1. In fact, if all
genes looked as perfect as FHL1, a simple average would suffice
and there would be no need for a method that down-weights bad
platforms or probes. For the SLC36A1 gene, the Agilent probes do
Figure 2. Medians and inter-quartile ranges (IQR’s) of gene expression values. Each dot in these plots is a gene. The x-axis is the median
expression value for a given gene over the 175 ovarian samples, and the y-axis is the IQR for that gene over the 175 samples. In the top row, 129
genes with all three ^ b b’s v0:5 are highlighted in red. In the bottom row, 40 genes with one negative ^ b b and two other ^ b b’s w0:5 are highlighted in the
platform where the ^ b b is negative.
doi:10.1371/journal.pone.0017691.g002
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(Figure 3B, Figure S13). U133 and Exon arrays have higher
pairwise correlations and get higher ^ b b values (Figure S14),
resulting in the factor analysis model basing its estimates mostly
on the two Affymetrix platforms (Figure 3D). We can also see from
the same figure that the average of the platform gene-level
summaries is influenced by the under-performing Agilent probes,
which is what we would like to avoid with the FA model.
In the probe-level model, the unified gene expression measure is
a weighted average of the probe measurements, and each probe
has a ^ b b value associated with it. The larger the ^ b b, the larger the
contribution from that probe to the unified measure. Figure 4 is
the probe-level equivalent of Figure 2 in the gene-level model. For
each platform, we highlight genes with low median probe ^ b b values,
and as in the gene-level model, they occur when the genes have
low expression values or small dynamic ranges. There are 69 genes
in which Heywood cases occur in the probe-level model fit, many
fewer than in the gene-level model fit.
Comparing gene-level and probe-level FA. Gene-level FA
and probe-level FA have their own advantages. Gene-level FA
Figure 3. Probe-level factor analysis. A, B: Log2 probe intensities of FHL1 and SLC36A1. Solid lines are U133 probes, dashed lines are Exon probes,
and dot-dashed lines are Agilent probes. The thicker solid black lines are gene summaries for U133, Exon and Agilent. For ease of visualization, a
constant of 10 and 22 are added to U133 and Agilent, respectively. Only the first 50 samples are used. C, D: Pairs plots of different gene summaries.
From top to bottom: U133, Exon, Agilent, gene-level FA, probe-level FA and gene-level average.
doi:10.1371/journal.pone.0017691.g003
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compute. Its disadvantage is that it can only work for genes that are
present on all three platforms. Probe-level FA eliminates the
requirementfora genetobepresentonallthreeplatforms,buttakes
hours to compute, and for some genes, fails to converge (149 in the
GBM dataset and 396 in the Ovarian dataset). Despite these
differences, 75% of the genes have gene-level and probe-level FA
correlations greater than 0.8 (Figure S15). There are 846 genes
where the correlation between gene-level and probe-level FA
estimates is less than 0:5. The majority of these genes have either
low expression levels or small dynamic ranges (Figure S16). After
these are removed (genes with U133 median v4, U133 IQR v0:2,
Exon median v5, Exon IQR v0:4, Agilent median v{1:2,a n d
Agilent IQR v0:4), there are 76 genes left with probe-level and
gene-levelFAcorrelationslessthan0:5.Amongthese,gene-levelFA
for 46 genes are Heywood cases, and therefore are not useful. For
the remaining 30 genes, all but four are such that U133 and Agilent
gene-level summaries correlate but not exon gene-level summaries.
Gene-level FA for these genes are mostly based on Agilent and
U133 gene-level summaries, as expected. However, probe-level FA
Figure 4. Medians and inter-quartile ranges (IQR’s) of gene expression values. Each dot in these plots is a gene. The x-axis is the median
expression value for a given gene over the 175 ovarian samples, and the y-axis is the IQR for that gene over the 175 samples. For a given gene, a
median ^ b b is calculated for each platform. In the top row, 114 genes with all three median ^ b b’s v0:2 are highlighted in red. In the bottom row, 14
genes with one negative median ^ b b and two other median ^ b b’s w0:5 are highlighted in the platform where the median ^ b b is negative.
doi:10.1371/journal.pone.0017691.g004
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is the result of the many more probes present on the Exon array
than the other two platforms. When measurements from the
majority of these probes do not agree with the other two platforms,
thegene summariesdo not agree with theothertwo platformseither
and get down-weighted in the gene-level FA. But in probe-level FA,
these probes become the majority and are the driving forces of the
probe-level FA estimates, which then do not agree with gene
summaries of the other two platforms. An example is the CCDC85B
gene (Figure S17), where gene-level FA is more accurate than
probe-level FA according to DGE data. For the aforementioned 30
genes, the majority have better correlations between gene-level FA
and DGE than between probe-level FA and DGE (Figure S18).
Based on these observations, gene-level FA seems to be a more
reliable method than the probe-level FA when the number of Exon
array probes is large.
Evaluation
To combine gene expression measures from several platforms,
the naive method would be to take the mean of the standardized
gene-level summaries of each platform. An alternative would be to
take the mean of the probe-level data from all platforms, or use
gene-level summaries from one of the platforms. Therefore we
have seven gene expression summaries: gene-level averages,
probe-level averages, RMA summaries of U133 arrays, RMA
summaries of Exon arrays, gene summaries of Agilent arrays,
gene-level FA and probe-level FA. We now evaluate these seven
gene expression summaries in terms of precision (variance) and
accuracy (bias). For precision, we use the nine sets of replicate
samples in our data and compare the variability of the seven gene
expression summaries. For accuracy, we use digital sequencing
data on 31 of the ovarian tumor samples as our gold standard.
Note that notations used in this section is independent of those in
the methods section.
Comparison of precision. There are 9 sets of replicate
samples: 06-0137 (2), 06-0138 (2), 06-0145 (4), 06-0154 (2), 06-
0156 (3), 06-0168 (2), 06-0176 (2), 06-0208 (2) and 06-0211 (2). For
a given gene, let yij denote the standardized gene expression
summary of the j th replicate of sample i. The pooled variance for
each gene expression summary is
Varpooled~
S9
i~1S
ni
j~1(yij{yi:)
2
S9
i~1(ni{1)
,
where ni is the number of replicates for sample i. We standardize
each gene expression summary to have mean 0 and standard
deviation 1 for each gene across samples so that they are
comparable. Figure 5A shows that gene-level FA and gene-level
averages have the smallest pooled standard deviations, and that
they give estimates that are the least variable.
Figure 5. Comparisons of precision and accuracy. A: Pooled standard deviations of standardized gene expression measures. The medians are
0.44, 0.44, 0.39, 0.31, 0.35, 0.33, 0.32 from left to right. B: Sum of squared differences between array summaries and tag profiling. The medians are
27.0, 26.1, 22.5, 21.4, 22.9, 23.9 and 21.3 from left to right. C: Sum of squared differences between gene-level averages and tag profiling, and between
gene-level factor analysis and DGE, for genes with exactly two b’s w 0.8.
doi:10.1371/journal.pone.0017691.g005
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emerging as an attractive alternative to microarrays for measuring
gene expression levels. Instead of relying on hybridization of
predetermined probes to target transcripts, the new sequencing
technologies count the number of reads mapped to genes of
interest, and thus eliminate issues with cross hybridization and
background signals. Studies find that gene expression measured
from next- generation sequencing is highly replicable and that its
performance in identifying differentially expressed genes is highly
concordant with qRT-PCR [10,11]. Gene expression of 31 of the
TCGA ovarian samples is measured using Illumina Tag Profiling,
also known as Digital Gene Expression Tag Profiling (DGE) [16],
a next generation sequencing technology based on serial analysis
of gene expression (SAGE) [17,18]. DGE has been shown to have
major improvements in robustness, resolution and inter-lab
reproducibility over microarray platforms ([19]). Therefore we
use DGE data as a reference and compare the performance of the
unified expression measures to that of the three platforms alone
and simple averages.
We use median-normalized Illumina DGE gene count data for
31 of the ovarian tumor samples as our reference for expression
levels. Processing of the DGE data is described in File S1.
Similarities between array summaries and DGE
data. As a first step to assess how well array gene expression
summaries resemble that of DGE data, we compute the sum of
squared differences between standardized array summaries and
Figure 6. Pairs plot of estimated log2 fold changes computed from different gene expression value estimates: U133 gene-level
summaries, Exon array gene-level summaries, Agilent gene-level summaries, gene-level averages across the three platforms,
probe-level averages across the three platforms, probe-level factor analysis estimates, gene-level factor analysis estimates, and
digital sequencing gene-level summaries. Spearman correlations are shown.
doi:10.1371/journal.pone.0017691.g006
Unified Gene Expression Measures
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let yij denote the standardized log2 expression measure for gene j from
sample i,a n dl e tzij denote the standardized log2 counts for gene j from
sample i of the median-normalized counts. The sum of squared
differences between an array platform and DGE for gene j is
SSj~
X k
i~1
(yij{zij)
2,
where k~31 is the number of samples. Figure 5B shows the SS
for the seven array summaries and we see that gene-level FA has
the smallest median SS and gives expression measures that are
closest to DGE.
Comparison of estimated fold changes. Instead of
quantifying absolute gene expression levels, we often use
microarrays to compare the expression levels of two groups by
estimating a fold change for each gene. Here we obtain two
distinct groups of sizes 7 and 24 from the 31 samples by consensus
clustering [20], denoted by L and G respectively (Figure S19),
representing possible subclasses of ovarian cancer. The log2 fold
change from DGE for gene j is estimated to be
FCseq,j~
1
24
X
i[G
zij{
1
7
X
i[L
zij,
where zij is the log2 counts for gene j from sample i of the median-
normalized counts. The log2 fold changes for array summaries are
computed in the same way by replacing zij with log2 gene
expression measurements yij for each of the seven gene
summaries obtained from array data. DGE produces fold
changes that do not correlate as well as correlations among the
array summaries (Figure 6), which is not very surprising as the
two technologies are fundamentally different. The different gene
summaries give fold change estimates that have similar
correlations with DGE.
Identifying differentially expressed genes. Poisson
regression models have been shown to work well across
technical strata for digital sequencing data [10,11]. However,
we find significant departures from the Poisson distribution
when examining qq-plots of x2 goodness-of-fit statistics
(Figure S20), possibly due to biological variation among the
samples.
Figure 7. ROC curves constructed for the seven gene summaries. Genes with adjusted p-values v0:05 for DGE are considered true positives
and genes with adjusted p-values w0:2 are considered true negatives. The area under the curves are indicated next to the gene summary methods in
the legend.
doi:10.1371/journal.pone.0017691.g007
Table 1. Configurations of b’s used in simulations.
b1 min b1 max b2 min b2 max b3 min b3 max
1 0.90 0.98 0.90 0.98 0.00 0.30
2 0.80 0.90 0.80 0.90 0.00 0.30
3 0.70 0.80 0.70 0.80 0.00 0.30
4 0.60 0.70 0.60 0.70 0.00 0.30
5 0.80 0.98 0.80 0.98 0.30 0.50
6 0.70 0.80 0.70 0.80 0.30 0.50
7 0.60 0.70 0.60 0.70 0.30 0.50
8 0.70 0.98 0.70 0.98 0.70 0.98
9 0.50 0.70 0.50 0.70 0.50 0.70
10 0.30 0.50 0.30 0.50 0.30 0.50
11 0.00 0.30 0.00 0.30 0.00 0.30
12 0.80 0.98 0.50 0.70 0.00 0.30
Two hundred genes are simulated for each configuration of b. For a given
range, b’s are simulated from the uniform distribution with that range.
doi:10.1371/journal.pone.0017691.t001
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two groups specified in section is significantly different from 0.
Rather than relying on methods based on the Poisson distribution,
we use limma [21,22] to perform a two-sample comparison on the
log2 count data from DGE, and adjust for multiple testing using
Benjamini and Hochberg [23]. We find 132 genes with adjusted p-
values v0:05 between the two groups from DGE data and regard
them as true positives. There are 10,057 genes with adjusted p-
values w0:2, and are thought of as true negatives that do not
display differential expression between the two groups. ROC
curves constructed from these genes show that gene-level FA,
probe-level FA, and gene-level averages perform the best in
identifying differentially expressed gene, and that they are the most
sensitive at specificities between 0.75 and 0.94 (Figure 7).
Summary of accuracy of gene expression measures. We
use DGE data on 31 of the ovarian tumor samples to assess the
accuracy of gene expression measurements from three microarray
platforms, their simple averages, and the proposed unified
expression measures. We find that the gene-level FA is the
closest to the expression measures generated from DGE when
Figure 8. Simulation study. Solid line: density of sum of squared differences (x-axis) between the true expression level and gene-FA estimates.
Dashed line: density of sum of squared differences between the true expression level and averages of the three platforms. Two hundred data sets are
simulated from each b configuration. The ranges of the three b values are indicated at the top of each subplot.
doi:10.1371/journal.pone.0017691.g008
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array summaries and standardized log2 median-normalized count
data from DGE, although gene-level averages of the three
platforms perform almost as well. The seven gene summaries
generate fold change estimates that have similar correlations with
those generated by DGE. Gene-level FA, probe-level FAs and
gene-level averages perform the best in identifying differentially
expressed genes when genes with adjusted p-values v0:05 and
w0:20 from DGE are used as true positives and negatives,
respectively. With these findings, we feel confident that the unified
expression measures produced from gene-level and probe-level
FAs perform better than probe-level averages, and at least as well
as simple gene-level averages in terms of accuracy.
Further comparison of gene-level FA and gene-level
averages
When looking across all the genes common to all three
platforms, it appears that gene-level FA and gene-level average
perform comparably. We perform a simulation study to evaluate
their behaviors more systematically. Based on the results of this
simulation study, we identify a subset of genes for which gene-level
FA shows an advantage over gene-level average in TCGA ovarian
data set.
The simulation procedure. We simulate gene expression
data for 200 samples according to the FA model described in
equation (1) as follows:
1. The true gene expression levels x1, x2, .., x200 for a given gene
of samples i~1,2,::,200 are simulated from N(0,1);
2. For a given configuration of b’s, generate b1, b2 and b3 from
uniform distributions of corresponding ranges. Then Y is
determined since bb
TzY has all 1’s on the diagonal;
3. Generate i1, i2 and i3 for i~1,2,::,200 from N(0,Y);
4. Determine yi1, yi2 and yi3 from yij~bjxiz ij for i~1,2,::,200;
5. Get estimates of x1, x2,. . ,x200 from yi1, yi2 and yi3,
i~1,2,:::,200, using gene-level FA and gene-level averages.
6. Repeat 200 times for each configuration of b.
Table 1 contains the different b values we chose to simulate
different situations that can arise in real data.
Simulation results. Figure 8 shows the difference between
estimated gene expression levels and true gene expression levels.
Gene expression levels are estimated using gene-level FA and
gene-level averages. The difference is represented by the sum of
squared differences across the 200 simulated datasets for each b
configuration.
Figure 9. Sum of squared differences between array summaries and digital sequencing measures for the 892 genes that have two
array platforms with 0.5 and above correlations with digital sequencing and the third array platform having a 0.4 and lower
correlation with digital sequencing. The medians from left to right: 30.1, 29.4, 22.5, 22.4, 24.8, 24.9 and 21.1.
doi:10.1371/journal.pone.0017691.g009
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PLoS ONE | www.plosone.org 12 March 2011 | Volume 6 | Issue 3 | e17691We see that gene-level FA has a clear advantage over the
average when two of the b’s are above 0.8 and the third b is below
0.5 (subplots 1, 2, 5). If the two best b’s are between 0.6 and 0.8
while the third b is below 0.3 (subplots 3 and 4), gene-level FA is
sometimes better and sometimes worse than the average. If the
third b improves to between 0.3 and 0.5 (subplots 6 and 7), gene-
level FA and the average become more similar to each other. The
two estimates are comparable when all three b’s are high (subplot
8 and 9). When one b is high, one is low and the third is in
between (subplot 12), gene-level FA does better most of the time,
but worse than the average on occasions. Gene-level FA does
worse when all three b’s are below 0.5 (subplots 10 and 11).
In general, the average is less sensitive than FA. The FA takes
advantage of the two good platforms when it is clear that the third
platform should be down-weighted, but can also produce worse
estimates than the average when the situation is less clear.
Ovarian data. With more insight from our simulation study,
we now look at a subset of genes where two of the array platforms
have better than 0.5 correlations with DGE and the third platform
has a correlation of 0.4 or less with DGE. There are 892 genes that
fall into this category. We find that the gene-level FA has an
advantage over the average in terms of distances to the expression
level measured by DGE for this subset of genes, while they remain
comparable in precision, fold-change and identification of DE
genes (data not shown).
Figure 9 shows the sum of squared differences between different
summaries and DGE. Gene-level FA performs the best with a
median of 21.1, followed by gene-level average, with a median of
22.4. The difference between the two widens if we restrict to genes
with two array and DGE correlations greater than 0.6 or the third
array platform having a correlation of 0.3 or worse with DGE.
Discussion
We propose to use the factor analysis model to produce a
unified gene expression measure from three different microarray
platforms (U133, Exon and Agilent) when the same set of samples
is measured on each. Factor analysis is a natural method to use
since it takes the covariance structure of the three platforms into
account and estimates the unobserved variable as a weighted
average of the three observed variables. This estimate is linear in
the observed variables, albeit one with estimated coefficients.
The main advantage of the proposed factor analysis model is that it
down-weights problematic platforms and therefore gives better
estimates than a simple average. This is shown clearly in simulations
(subplots 1 to 6). With real data, we do not expect the factor analysis
model to show a drastic improvement over the simple average simply
because the fraction of genes where one platform is misbehaving is
small. However, when this does happen, the gene-level FA produces
estimates that are more accurate than the simple average (Figures 5C).
The other advantage of our method is that it produces parameter
estimates (b and Y) that can be used to evaluate the model fit and to
filter out genes whose measurements are deemed unreliable, which was
done for Verhaak et al [4].
The unified expression measures generated from the FA model
was successfully used in a recent analysis of TCGA GBM
expression profiles [4]. In this analysis, four robust unsupervised
clusters were identified, which were associated with distinct
genomic abnormalities in IDH1, EGFR, PDGFRA and NF1.
Interestingly, the classifier cross-validation errors were reduced
when gene-level FA expression levels were used, compared to
training the classifier models on data from any of the three
separate platforms. Reduction in cross-validation error has been
shown to be a property of less noisy data [24].
TCGA is expected to produce expression profiles on three
platforms on a total of 1,500 tumor samples of GBM, ovarian
serous adenocarcinoma and lung squamous carcinoma, to which
FA will be applied to produce unified expression estimates and
will be made available at http://tcga-data.nci.nih.gov/docs/
publications/unified_expression/. The factor analysis model may
be further improved to produce good estimates when the
correlation matrix is poorly estimated, which usually occurs for
genes with a small dynamic range. An approach that allows us to
borrow information from genes with well-estimated correlation
matrices could improve the estimates for such genes.
Supporting Information
Figure S1 Correlation of gene-level summaries among the three
platforms per gene.
(TIF)
Figure S2 Estimated ^ b b values of the three platforms per gene.
(TIF)
Figure S3 Estimated ^ b b values for genes where one of the platforms
does not correlate with the other two. These are genes where one
pairwise correlation between two platforms is w0:6 and two others are
v0:4. Gene counts are given in parenthesis in panel titles.
(TIF)
Figure S4 GBM data. Gene SLC36A1: Gene-level summaries.
(TIF)
Figure S5 Gene SLC36A1: Gene-level summaries.
(TIF)
Figure S6 Correlations for 53 genes with one bad ^ b b value
(v0:5) when the gene is expressed at a reasonable level (w6 for
U133 and Exon, w{2 for Agilent) with a reasonable dynamic
range (IQR w0:5) on all three platforms, which are likely due to
annotation errors. The low ^ b b value is associated with the platform
that is not concordant with the other two.
(TIF)
Figure S7 Heywood cases. Red dots are genes in which
Heywood cases occur.
(TIF)
Figure S8 Bootstrap SE of ^ b b.
(TIF)
Figure S9 Genes with large bootstrap SE of ^ b b. Red dots are
genes with bootstrap SE of ^ b bw0:2.
(TIF)
Figure S10 Number of probes per gene on each platform.
Figures reflect the number of unique probes on the Agilent array,
each usually duplicated 2 to 3 times.
(TIF)
Figure S11 Pairwise probe correlations for gene FHL1 stratified
into three within-platform groups and three between-platform groups.
FHL1 has 55 U133 probes, 52 exon probes, and 3 Agilent probes.
Therefore there are 55|54=2 correlations within U133, 52|51=2
correlations within exon, 3|2=2 correlations within Agilent, 55|52
correlations between U133 and exon, 55|3 correlations between
U133 and Agilent, and 52|3 correlations between exon and Agilent.
(TIF)
Figure S12 Gene FHL1: probe-level ^ b b values stratified by
platform.
(TIF)
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PLoS ONE | www.plosone.org 13 March 2011 | Volume 6 | Issue 3 | e17691Figure S13 Pairwise probe correlations for gene SLC36A1 stratified
into three within-platform groups and three between-platform groups.
SLC36A1 has 11 U133 probes, 49 exon probes, and 2 Agilent probes.
Therefore there are 11|10=2 correlations within U133, 49|48=2
correlations within exon, 1 correlation within Agilent, 11|49
correlations between U133 and exon, 11|2 correlations between
U133 and Agilent, and 49|2 correlations between exon and Agilent.
(TIF)
Figure S14 Gene SLC36A1: probe-level ^ b b values stratified by
platform.
(TIF)
Figure S15 Histogram of 11,864 correlations between matching
gene-level and probe-level gene expression estimates.
(TIF)
Figure S16 Genes with low correlation between probe-level FA
and gene-level FA. Red dots are genes whose correlation between
probe-level FA and gene-level FA estimates are below 0:5.
(TIF)
Figure S17 Gene CCD85B. Probe-level FA strongly influenced
by Exon array because of its large number of probes.
(TIF)
Figure S18 Correlations between gene-level FA and DGE, and
correlations between probe-level FA and DGE for 30 genes with
low probe-level and gene-level FA correlations. These genes have
reasonable expression levels and dynamic ranges, and are not
Heywood cases.
(TIF)
Figure S19 Consensus clustering of the 31 ovarian samples.
Samples 1 to 7 form cluster 1 (C1) and samples 8 to 31 form cluster
2 (C2).
(TIF)
Figure S20 QQ-plot of x2 goodness-of-fit statistics for 24
samples from patients in cluster 2. Under the assumption of
homogeneous Poisson rate for the gene counts, the goodness-of-fit
statistics is x2 with 23 degrees of freedom. We see significant
deviations from homogeneous Poisson distribution.
(TIF)
Table S1 Number of genes with varying b cutoffs for all three
platforms.
(PDF)
Table S2 Percentage of small b’s.
(PDF)
Table S3 Number of genes with varying b cutoffs for all three
platforms.
(PDF)
File S1 File describing the processing of DGE data.
(PDF)
File S2 R code.
(TXT)
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